EAACI Congress 2025
BackSAT07 - Pharming – A new era in APDS management: Tackling PI3K hyperactivity at its source
Objectives
Activated PI3 kinase delta syndrome (APDS) is a rare, unpredictable and life-limiting disease that can progress rapidly at any point and is caused by hyperactivity of the PI3K delta pathway. During this session, we will discuss the challenges in diagnosing APDS, explore current unmet treatment needs and introduce Joenja®▼(leniolisib), the first and only disease-specific therapy licenced for APDS. Discussions will include insights into real-world clinical experience with Joenja as well as an overview of efficacy and safety data.
▼Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events and product complaints should also be reported to Pharming by emailing safety@pharming.com.
This meeting has been sponsored and fully funded by Pharming. For Joenja (leniolisib) prescribing information for the UK, please visit https://www.pharming.com/HCPPrescribingInformationUK.pdf.
LEN-UK-2025-0092 | April 2025
